Status
Conditions
Treatments
About
Visfatin, released in maternal milk at different concentrations related to the maternal conditions, could act as a biomarker with a prognostic/predictive value to determine different newborn clinical conditions, particularly the weight loss of the neonate.
Full description
The aim of the study is to analyse a retrospective cohort of well characterized mothers in their post-partum period, and to measure Visfatin levels through collection of maternal milk samples. They will be collected in three different moments after the birth (48 hours, 7 days and 30 days) and Visfatin levels will be analysed through an ELISA kit Adipogen. In parallel, the levels of Visfatin will be evaluated in the maternal plasma/serum collected after 1-2 days postpartum.
Lastly, correlations between Visfatin levels and biological/clinical features of mothers and newborns will be explored.
Enrollment
Sex
Volunteers
Inclusion criteria
Exclusion criteria
Loading...
Central trial contact
Paolo Manzoni, Professor
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal